Advent International is reportedly considering selling Zentiva, a generic drugmaker previously owned by Sanofi, for a potential valuation of around €5 billion ($5.4 billion).
The private equity firm, which acquired Zentiva in 2018, is working with Goldman Sachs Group Inc. and PJT Partners to explore strategic options for the business.
Interest in Zentiva is expected to come from various buyout firms and financial investors looking to expand their presence in the pharmaceutical sector. This move reflects the ongoing trend of firms seeking opportunities in the generic drug space.